Regeneron Pharmaceuticals, Inc. (REGN) Stock Overview
Explore Regeneron Pharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Regeneron Pharmaceuticals, Inc. (REGN)
Key Financials
Key Financials
Market Cap
63.9B
P/E Ratio
14.64
EPS (TTM)
$45.63
ROE
0.14%
REGN Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Regeneron Pharmaceuticals, Inc. (REGN) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 43.75, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $875.98.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 14.64 and a market capitalization of 63.9B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.